Puma Biotechnology | PBYI - Loan Capital


Puma Biotechnology reported $10.87M in Loan Capital for its fiscal quarter ending in June of 2025.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Daiichi Sankyo JPY 500B 199.92B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Incyte USD 28.42M 994K Jun/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Moderna USD 597M 6M Jun/2026
Novartis USD 37.49B 42M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Takeda JPY 4.42T 50.32B Jun/2026
TG Therapeutics USD 745.39M 247K Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025